Palabras clave
Consenso de expertos
Tratamiento
diagn´óstico
tratamiento
Datos de los fondos
Resumen
Introducción: La dermatitis atópica es una enfermedad crónica, sistémica, reincidente, con manifestaciones dermatológicas, que impone una alta carga a los pacientes, las familias y los sistemas de salud, y tiene repercusión psicológica, social y económica, y en la calidad de vida de los pacientes. Afecta principalmente a la población pediátrica y con menor frecuencia a la adulta. Las manifestaciones clínicas varían según la edad y evolución de la enfermedad, y en la actualidad se dispone de múltiples opciones farmacológicas y no farmacológicas para el tratamiento de los pacientes.
Objetivo: Presentar un algoritmo de tratamiento de la dermatitis atópica, propuesto con una serie de recomendaciones acerca del diagnóstico, tratamiento y seguimiento de los pacientes.
Métodos: Se llevó a cabo un consenso de expertos, utilizando la técnica del grupo nominal. La metodología se desarrolló en 7 fases que incluyeron: planteamiento de las preguntas de investigación, búsqueda de la bibliografía, propuesta inicial de las recomendaciones, elaboración de las recomendaciones finales y del algoritmo de tratamiento con tres ciclos de votación. Se estableció el consenso con un 80% de favorabilidad.
Resultados y conclusiones: El resultado del consenso fue un algoritmo de tratamiento de pacientes con dermatitis atópica leve, moderada-grave, derivado de las recomendaciones de expertos. En el algoritmo se establecen criterios diagnósticos y de tratamiento, y se aportan recomendaciones actualizadas que incluyen las alternativas disponibles en Perú.
Referencias
Giachetti A, Castro C, Greco MF, Scacchi MF, et al. Consenso Nacional de Dermatitis Atópica 2013. Resumen ejecutivo. Arch Argent Pediatr. 2014; 12 (3): 293-4. DOI: 10.5546/aap.2014.293
Sastre J, Baldrich ES, Armario Hita JC, Herraéz L, et al. Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey. Dermatol Res Pract. 2020; 2020. DOI: 10.1155/2020/1524293
Slattery MJ, Essex MJ, Paletz EM, Vanness ER, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011; 128 (3): 668. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164894/
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018; 32 (5): 657-82. DOI: 10.1111/jdv.14891
Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol . 2018; 36 (5): 595-605. https://pubmed.ncbi.nlm.nih.gov/30217272/
Son JH, Chung BY, Kim HO, Park CW. Clinical features of atopic dermatitis in adults are different according to onset. J Korean Med Sci. 2017; 32 (8): 1360-6. https://pubmed.ncbi.nlm.nih.gov/28665074/
Magnifico I, Petronio GP, Venditti N, Cutuli MA, et al. Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy? Pharmaceuticals. 2020; 13 (11): 1-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700401/
Nacional C, Dra DD, Giachetti A, María D, et al. Consenso Nacional de Dermatitis Atópica 2013. Arch Argent Pediatr. 2014; 1-21. DOI: 10.5546/aap.2014.293
Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980; (92 (Suppl 1): 44-7.
Wüthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome: Epidemiology, natural course, and immunology of the IgE-associated (“extrinsic”) and the nonallergic (“intrinsic”) AEDS. J Invest Allergol Clin Immunol. 2003; 13 (1): 1-5. https://pubmed.ncbi.nlm.nih.gov/12861844/
Wollenberg A, Oranje A, Deleuran M, Simon D, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatology Venereol. 2016; 30 (5): 729-47. https://pubmed.ncbi.nlm.nih.gov/27004560/
Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatology Venereol. 2019; 33 (9): 1644-59. DOI: 10.1111/jdv.15709
Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, et al. Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther. 2019; 32 (6): 1-10. DOI: 10.1111/dth.13121
McMillan SS, King M TM. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016; 38 (3): 655-62. DOI: 10.1007/s11096-016-0257-x
Potter M, Gordon S, Hamer WP. The Nominal Group Technique: A Useful Consensus Methodology in Physiotherapy Research. New Zeal J Physiother. 2008; 32: 126-30. https://www.researchgate.net/publication/254724490_The_Nominal_Group_Technique_
A_useful_consensus_methodology_in_physiotherapy_research
Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995; 311 (7001): 376-80. DOI: 10.1136/bmj.311.7001.376.
Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy Eur J Allergy Clin Immunol Suppl. 2004; 59 (78): 86-92. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1398-9995.2004.00569.x
Kulthanan K, Tuchinda P, Nitiyarom R, Chunharas A, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. Asian Pacific J Allergy Immunol. 2021; 39 (3): 145-55. DOI: 10.12932/AP-010221-1050
Russo F, Milanesi N, Iannone M, Bagnoni G, et al. Tuscan Consensus on the diagnosis, treatment and follow-up of adult atopic dermatitis. G Ital di Dermatologia e Venereol. 2020; 155 (3): 253-60. DOI: 10.23736/S0392-0488.19.06527-1
Costanzo A, Amerio P, Asero R, Chiricozzi A, et al. Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian
Associ. Ital J Dermatology Venereol. 2022; 157 (1): 1-12. DOI: 10.23736/S2784-8671.21.07129-2
Rincón-Pérez C, Larenas-Linnemann D, Figueroa-Morales MA, Luna-Pech J, et al. Mexican consensus on the diagnosis and treatment of atopic dermatitis in adolescents and adults. Rev
Alerg Mex. 2018; 65: S8-88. DOI: 10.29262/ram.v65i6.526
2Hong CH, Gooderham MJ, Albrecht L, Bissonnette R, et al. Approach to the assessment and management of adult patients with atopic dermatitis: A consensus document. Section v: Consensus statements on the assessment and management of adult patients with moderate-to-severe atopic dermatitis. J Cutan Med Surg. 2018; 22: 30S-35S. DOI: 10.1177/1203475418803625
Patruno C, Amerio P, Chiricozzi A, Costanzo A, et al. Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: Joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergologic. G Ital di Dermatologia e Venereol. 2020; 155 (1): 1-7. DOI: 10.23736/S0392-0488.19.06522-2
Kannenberg SM, Karabus S, Visser WI, Aboobaker J, et al. Paediatric atopic eczema (Atopic dermatitis) in south africa: A practical algorithm for the management of mild-to-moderate disease in daily clinical practice. South African Fam Pract. 2020; 62 (1): 1-9. DOI: 10.4102/safp.v62i1.5190
Agache I, Song Y, Posso M, Alonso-Coello P, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy Eur J Allergy Clin Immunol. 2021; 76 (1): 45-58. DOI: 10.1111/all.14510
Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract. 2020; 8 (1): 91-101. DOI: 10.1016/j.jaip.2019.06.044
Rullo VEV, Segato A, Kirsh A, Sole D. Severity scoring of atopic dermatitis: a comparison of two scoring systems. Allergol Immunopathol (Madr). 2008; 36 (4): 205-11. http://dx.doi.org/10.1016/S0301-0546(08)72551-5
Kim JE, Shin MK, Park GH, Lee UH, et al. 2019 consensus Korean diagnostic guidelines to define severity classification and treatment refractoriness for atopic dermatitis: Objective and subjective assessment of severity. Ann Dermatol. 2019; 31 (6): 654-61. DOI: 10.5021/ad.2019.31.6.654
Perez-Chada L, Taliercio VL, Gottlieb A, Van Beek M, et al. Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.09.008
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, et al. Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatology. 2020; 156 (8): 863-73. DOI: 10.1001/jamadermatol.2020.1406
Chopra R, Silverberg JI. Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol. 2018; 36 (5): 606-15. https://doi.org/10.1016/j.clindermatol.2018.05.012
Yang YB, Lynde CW, Fleming P. Common Atopic Dermatitis Rating Scales: A Practical Approach and Brief Review. J Cutan Med Surg. 2020; 24 (4): 399-404. DOI: 10.1177/1203475420923644
Calzavara-Pinton P, Fortina AB, Bonamonte D, Marseglia GL, et al. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDemaSt), the Italian association of Hospital Dermatologists and Public Health (aDoI), the Italian associa. Ital J Dermatology Venereol. 2021; 156 (2): 184-97. DOI: 10.23736/S2784-8671.20.06654-7
Smith S, Baker C, Gebauer K, Rubel D, et al. Atopic dermatitis in adults: An Australian management consensus. Australas J Dermatol. 2020; 61 (1): 23-32. DOI: 10.1111/ajd.13124
Barbarot S, Boralevi F, Shourick J, Sampogna F, et al. Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education. J Eur Acad Dermatology Venereol. 2021; 35 (11): 2263-9. DOI: 10.1111/jdv.17526
Dhadwal G, Albrecht L, Gniadecki R, Poulin Y, et al. Approach to the assessment and management of adult patients with atopic dermatitis: A consensus document. Section IV: Treatment options for the management of atopic dermatitis. J Cutan Med Surg. 2018; 22: 21S-29S. DOI: 10.1177/1203475418805721
Reda AM, Elgendi A, Ebraheem AI, Aldraibi MS, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019; 30 (4): 366-73. https://doi.org/10.1080/09546634.2018.1524823
Patrizi A, Costanzo A, Patruno C, Busà VM, et al. Unmet needs in atopic dermatitis management: an expert consensus. J Dermatolog Treat. 2022; 33 (5): 2459-65. https://doi.org/10.1080/09546634.2021.1967267
Iannone M, Tonini G, Janowska A, Dini V, et al. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review. Curr Med Res Opin. 2021; 37 (8): 1295-301. https://doi.org/10.1080/03007995.2021.1933929
Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. Br J Dermatol. 2021; 185 (1): 139-46. DOI: 10.1111/bjd.19751
Boguniewicz M, Alexis AF, Beck LA, Block J, et al. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017; 5 (6): 1519-31. https://doi.org/10.1016/j.jaip.2017.08.005
Lynde CW, Bourcier M, Gooderham M, Guenther L, et al. A treatment algorithm for moderate to severe atopic dermatitis in adults. J Cutan Med Surg. 2018; 22 (1): 78-83. DOI: 10.1177/1203475417733460
Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, et al. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. J Allergy Clin Immunol Pract. 2021; 9 (3): 1053-65. DOI: 10.1016/j.jaip.2020.11.034
Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019; 28 (7): 756-68. DOI: 10.1111/exd.13911
Li H, Zhang Z, Zhang H, Guo Y, et al. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021; 61 (3): 324-38. https://doi.org/10.1007/s12016-021-08880-3
Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018; 178 (3): 768-75. DOI: 10.1111/bjd.15928
Boguniewicz M. Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines. J Allergy Clin Immunol Pract. 2017; 5 (6): 1477-87. https://doi.org/10.1016/j.jaip.2017.08.031
Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, et al. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020; 2020 (9). DOI: 10.1002/14651858.CD013206.pub2
Ghazal S, Ridha Z, Nassim D, D’aguanno K, et al. 456 Mapping recommendations of recent guidelines for adult atopic dermatitis. J Invest Dermatol. 2021; 141 (5): S79. DOI: 10.1016/j.jid.2021.02.479
Calzavara Pinton P, Cristaudo A, Foti C, Canonica GW, et al. Diagnosis and management of moderate to severe adult atopic dermatitis: A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Cli. G Ital di Dermatologia e Venereol. 2018; 153 (2): 133-45. DOI: 10.23736/S0392-0488.17.05892-8
Zhou S, Qi F, Gong Y, Zhang J, et al. Biological Therapies for Atopic Dermatitis: A Systematic Review. Dermatology. 2021; 237 (4): 542-52. DOI: 10.1159/000514535
Silverberg JI, Toth D, Bieber T, Alexis AF, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III EC ZTRA 3 trial*. Br J Dermatol. 2021; 184 (3): 450-63. DOI: 10.1111/bjd.19573
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, et al. Treat-to-target in atopic dermatitis: An international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021; 101 (2): 1-7. DOI: 10.2340/00015555-3751
Lopes C, Neto M, Rageteiro F, Marcelino J, et al. Protocolo clínico de avaliação de doentes adultos com dermatite atópica em tratamento com Dupilumab. Rev Port Imunoalergologia. 2019; 27 (2): 135-45.
Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol. 2022; 149 (3): 977-987.e14. https://doi.org/10.1016/j.jaci.2021.07.036
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatology Venereol. 2021; 35 (9): 1797-810. DOI: 10.1111/jdv.17351
Simpson EL, Sinclair R, Forman S, Wollenberg A, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020; 396 (10246): 255-66. http://dx.doi.org/10.1016/S0140-6736(20)30732-7
Custo Greig E, Brigell M, Cao F, Levine ES, et al. Macular and Peripapillary Optical Coherence Tomography Angiography Metrics Predict Progression in Diabetic Retinopathy: A Sub-analysis of TIME-2b Study Data. Am J Ophthalmol. 2020; 219: 66-76. https://pubmed.ncbi.nlm.nih.gov/32574773/
Agache I, Akdis CA, Akdis M, Brockow K, et al. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy Eur J Allergy Clin Immunol. 2021; 76 (4): 988-1009. DOI: 10.1111/all.14690
Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, et al. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb. J Allergy Clin Immunol. 2019; 143 (1): 135-41. DOI: 10.1016/j.jaci.2018.05.029
Newsom M, Bashyam AM, Balogh EA, Feldman SR, et al. New and Emerging Systemic Treatments for Atopic Dermatitis. Drugs. 2020; 80 (11): 1041-52. https://doi.org/10.1007/s40265-020-01335-7
Singh R, Heron CE, Ghamrawi RI, Strowd LC, et al. Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. ImmunoTargets Ther. 2020; 9: 255-72. DOI: 10.2147/itt.s229667
LeBovidge JS, Elverson W, Timmons KG, Hawryluk EB, et al. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016; 138 (2): 325-34. http://dx.doi.org/10.1016/j.jaci.2016.04.003
Borzutzky A, Larco JI, Luna PC, McElwee E, et al. Atopic Dermatitis in Latin America: A Roadmap to Address Data Collection, Knowledge Gaps, and Challenges. Dermatitis. 2022; 33 (6S): S83-S91. DOI: 10.1097/DER.0000000000000904.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2023 Revista Alergia México